CD274 and melanoma: Morales-Betanzos et al. demonstrated, using mass spectrometry and immunohistochemistry on 22 human melanoma samples, a discrepancy in PD-L1 expression assessed by the two methods, which the authors attributed to the aberrant PD-L1 glycosylation interfering with the antibody binding on immunohistochemistry [147].